Literature DB >> 17698973

Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort.

Jasmeet K Gill1, Gertraud Maskarinec, Lynne R Wilkens, Malcolm C Pike, Brian E Henderson, Laurence N Kolonel.   

Abstract

Previous studies on nonsteroidal antiinflammatory drugs (NSAIDs) and breast cancer have produced mixed results. Incident invasive cases of breast cancer from the Multiethnic Cohort (African Americans, Caucasians, Japanese Americans, Latinas, and Native Hawaiians from Hawaii and California) were identified from 1993 to 2002. Data on aspirin, acetaminophen, and other NSAID (ibuprofen, naproxen, indomethacin) use were based on a self-administered questionnaire at baseline (1993-1996). Multivariate Cox proportional hazards models provided estimates of hazard rate ratios and 95% confidence intervals. The authors observed no associations between breast cancer risk and duration of aspirin use for current or past users (hazard rate ratio = 1.05, 95% confidence interval: 0.88, 1.25 and hazard rate ratio = 1.04, 95% confidence interval: 0.84, 1.27 for > or =6 years of use, respectively) compared with nonusers. However, duration of current other NSAID use was protective (hazard rate ratio = 0.70, 95% confidence interval: 0.51, 0.95 for > or =6 years of use; p(trend) = 0.01) against the risk of breast cancer, while past use was not (hazard rate ratio = 0.90, 95% confidence interval: 0.62, 1.30 for > or =6 years of use). Analyses by ethnicity and hormone receptor status showed that the protective effect of current other NSAID use was limited to Caucasians and African Americans and to women with at least one positive hormone receptor. This study found duration of current other NSAID use to be protective against breast cancer risk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17698973     DOI: 10.1093/aje/kwm195

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  33 in total

1.  Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype.

Authors:  Theodore M Brasky; Matthew R Bonner; Kirsten B Moysich; Christine B Ambrosone; Jing Nie; Meng Hua Tao; Stephen B Edge; Bhaskar V S Kallakury; Catalin Marian; David S Goerlitz; Maurizio Trevisan; Peter G Shields; Jo L Freudenheim
Journal:  Cancer Causes Control       Date:  2011-04-23       Impact factor: 2.506

2.  Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study.

Authors:  E H Allott; C-K Tse; A F Olshan; L A Carey; P G Moorman; M A Troester
Journal:  Breast Cancer Res Treat       Date:  2014-08-24       Impact factor: 4.872

Review 3.  Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.

Authors:  Jocelyn Reader; Dawn Holt; Amy Fulton
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

4.  Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs.

Authors:  Louise R Howe; Scott M Lippman
Journal:  J Natl Cancer Inst       Date:  2008-10-07       Impact factor: 13.506

5.  Use of nonsteroidal anti-inflammatory drugs and reduced breast cancer risk among overweight women.

Authors:  Yong Cui; Sandra L Deming-Halverson; Martha J Shrubsole; Alicia Beeghly-Fadiel; Hui Cai; Alecia M Fair; Xiao-Ou Shu; Wei Zheng
Journal:  Breast Cancer Res Treat       Date:  2014-07-02       Impact factor: 4.872

Review 6.  The Role of NSAIDs in Breast Cancer Prevention and Relapse: Current Evidence and Future Perspectives.

Authors:  Demetrios Moris; Michalis Kontos; Eleftherios Spartalis; Ian S Fentiman
Journal:  Breast Care (Basel)       Date:  2016-10-24       Impact factor: 2.860

7.  Analgesic use and sex steroid hormone concentrations in postmenopausal women.

Authors:  Margaret A Gates; Shelley S Tworoger; A Heather Eliassen; Stacey A Missmer; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-23       Impact factor: 4.254

8.  Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial.

Authors:  Patricia A Thompson; Chiu-Hsieh Hsu; Sylvan Green; Alison T Stopeck; Karen Johnson; David S Alberts; H-H Sherry Chow
Journal:  Cancer Prev Res (Phila)       Date:  2010-01

9.  Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study.

Authors:  Deirdre P Cronin-Fenton; Lars Pedersen; Timothy L Lash; Søren Friis; John A Baron; Henrik T Sørensen
Journal:  Breast Cancer Res       Date:  2010-03-01       Impact factor: 6.466

10.  Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence.

Authors:  Xuehong Zhang; Stephanie A Smith-Warner; Laura C Collins; Bernard Rosner; Walter C Willett; Susan E Hankinson
Journal:  J Clin Oncol       Date:  2012-08-27       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.